News for Vivos Therapeutics, Inc. (VVOS)

Discover key insights from Vivos Therapeutics' Q1 2025 earnings call.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2025 Earnings Conference Call May 15, 2025 5:00 PM ETCompany ParticipantsBrad Amman - CFOKirk Huntsman - Chairman...

Revenue: $3.0 million for Q1 2025, falling short of the estimated $3.67 million, reflecting a strategic pivot away from legacy service revenue.Net Loss: Increa

Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisiti

Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of -2.27% and 18.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

**media[627618]**

Call Scheduled for Thursday, May 15, 2025 at 5:00 pm ET LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (”œVivos” or the ”œC

Vivos Therapeutics (VVOS) will release its Q1 2025 financial results on May 15, 2025, after market close.The company will host a conference call at 5:00 PM ET

Vivos Therapeutics (VVOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas

\n Vivos Therapeutics (VVOS) has signed a definitive agreement to acquire the largest sleep center operator in Nevada for up to $9 million. The Sleep Cente

Total Revenue: $15 million in 2024, up from $13.8 million in 2023, a 9% increase.Product Revenue: $7.9 million from oral appliance sales, a 26% increase from 2

Mar 31, 2025 / 09:00PM GMTOperator Good day, everyone, and welcome to the Vivos Therapeutics Full Year 2024 Earnings Conference Call. (Operator Instructions) Th

Discover key insights from Vivos Therapeutics' Q4 2024 earnings: strategic pivots, revenue growth, and expansion plans position them for a profitable 2025.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ETCompany ParticipantsBradford Amman - CFO, Treasurer &...

Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of 34.88% and 5.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[582034]**

**media[579434]**

**media[548599]**